Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.
(/) Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 1981;48:1426-37. (2) Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematoll994;31:31-7. (3) Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995; 13: 1238-41. (4) Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995; 13:1966-74. (5) Lazzanno M, Corso A, Regazzi MB, Iacona I, Bernasconi C. Modulation of a\\-trans retinoic acid pharmacokinetics in acute promyelocytic leukemia by prolonged interferon-a therapy. BrJHaematol 1995;90:928-30. (6) Toma S, Iacona 1, Palumbo R, Moresco L, Raffo P, Regazzi MB. Modulation of alltrans-retinoic acid administered on intermittent schedule by alpha-interferon 2a in a patient with AIDS-related Kaposi's sarcoma. AIDS1995;10:1049-50.